Wyeth welcomes NICE review of Torisel
Wyeth has welcomed news that the UK's National Institute for Health and Clinical Excellence (NICE) is reconsidering its position regarding the US drug major's Torisel (temsirolimus) for the treatment of kidney cancer.
The NICE issued preliminary guidance on August 6, recognizing that Torisel was clinically effective, but rejected the drug on the basis of it not being cost-effective. Wyeth says it had expressed concern to the NICE that, if its normal appraisal criteria were used to evaluate Torisel, then inevitably it would not find the drug to be cost-effective as it is indicated for a condition with only around 390 patients in England and Wales eligible for treatment with it each year.
Wyeth's medical director, Vignesh Rajah, said: "we very much hope that following this extended consultation period NICE will review Torisel using criteria more appropriate for drugs for very rare conditions."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze